UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cholera toxin: A paradigm for multi-functional engagement of cellular mechanisms (Review)

Molecular membrane biology, 2004-03, Vol.21 (2), p.77-92

2004

Volltextzugriff (PDF)

Monoclonal antibody therapeutics: history and future

Current opinion in pharmacology, 2012-10, Vol.12 (5), p.615-622

2012

Volltextzugriff (PDF)

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.1024-1038

2018

Volltextzugriff (PDF)

The future trajectory of adverse outcome pathways: a commentary

Archives of toxicology, 2018-04, Vol.92 (4), p.1657-1661

2018

Volltextzugriff (PDF)

Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice

Frontiers in immunology, 2023-03, Vol.14, p.1107848-1107848

2023

Volltextzugriff (PDF)

Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in rats

Toxicology and applied pharmacology, 2018-09, Vol.355, p.147-155

2018

Volltextzugriff (PDF)

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

Oncoimmunology, 2017-03, Vol.6 (3), p.e1280645-e1280645

2017

Volltextzugriff (PDF)

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity

Vaccine, 2001-04, Vol.19 (20), p.2898-2907

2001

Volltextzugriff (PDF)

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant

Molecular therapy, 2024-06, Vol.32 (6), p.1672-1686

2024

Volltextzugriff (PDF)

Reviewing the Utility of Two Species in General Toxicology Related to Drug Development

International journal of toxicology, 2018-03, Vol.37 (2), p.121-124

2018

Volltextzugriff (PDF)

Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach

Regulatory toxicology and pharmacology, 2023-02, Vol.138, p.105329, Article 105329

2023

Volltextzugriff (PDF)

Challenges and approaches for the development of safer immunomodulatory biologics

Nature reviews. Drug discovery, 2013-04, Vol.12 (4), p.306-324

2013

Volltextzugriff (PDF)

Enhanced Delivery of Exogenous Peptides into the Class I Antigen Processing and Presentation Pathway

Infection and Immunity, 2002-06, Vol.70 (6), p.3249-3258

2002

Volltextzugriff (PDF)

Mutant Escherichia coli Heat-Labile Toxin B Subunit That Separates Toxoid-Mediated Signaling and Immunomodulatory Action from Trafficking and Delivery Functions

Infection and Immunity, 2003-03, Vol.71 (3), p.1527-1537

2003

Volltextzugriff (PDF)

The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain

Regulatory toxicology and pharmacology, 2023-02, Vol.138, p.105339, Article 105339

2023

Volltextzugriff (PDF)

Trafficking of Exogenous Peptides into Proteasome-dependent Major Histocompatibility Complex Class I Pathway following Enterotoxin B Subunit-mediated Delivery

The Journal of biological chemistry, 2004-12, Vol.279 (49), p.51315-51322

2004

Volltextzugriff (PDF)

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Regulatory toxicology and pharmacology, 2020-06, Vol.113, p.104624, Article 104624

2020

Volltextzugriff (PDF)

Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5085-5085

2024

Volltextzugriff (PDF)

Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3122-3122

2024

Volltextzugriff (PDF)

Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights

Regulatory toxicology and pharmacology, 2016-10, Vol.80, p.S1-S14

2016

Volltextzugriff (PDF)

Current challenges and opportunities in nonclinical safety testing of biologics

Drug discovery today, 2013-12, Vol.18 (23-24), p.1138-1143

2013

Volltextzugriff (PDF)

Abstract 1604: Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1604-1604

2023

Volltextzugriff (PDF)

Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2638-2638

2023

Volltextzugriff (PDF)

Effect of human OX40 ligand fusion protein (MEDI6383) on immune cells of the humoral and cell-mediated immune response in a non-human primate model

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3052-3052

2015

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(45)
Buchkapitel
(1)

Sprache

Englisch
(46)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Animals
(27)
Humans
(18)
Pharmacology & Pharmacy
(14)
Immunology
(11)
Mice
(11)
Toxicology
(11)
Escherichia Coli Proteins
(8)
Legal Medicine
(8)
Medicine, Legal
(8)
Microbiology
(8)
Biological And Medical Sciences
(7)
Escherichia Coli
(7)
Female
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Enterotoxins - Immunology
(6)
Adjuvant
(5)
Bacterial Toxins - Immunology
(5)
Enterotoxins - Chemistry
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cholera toxin: A paradigm for multi-functional engagement of cellular mechanisms (Review)

Monoclonal antibody therapeutics: history and future

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

The future trajectory of adverse outcome pathways: a commentary

Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice

Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in rats

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant

Reviewing the Utility of Two Species in General Toxicology Related to Drug Development

Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach

Challenges and approaches for the development of safer immunomodulatory biologics

Enhanced Delivery of Exogenous Peptides into the Class I Antigen Processing and Presentation Pathway

Mutant Escherichia coli Heat-Labile Toxin B Subunit That Separates Toxoid-Mediated Signaling and Immunomodulatory Action from Trafficking and Delivery Functions

The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain

Trafficking of Exogenous Peptides into Proteasome-dependent Major Histocompatibility Complex Class I Pathway following Enterotoxin B Subunit-mediated Delivery

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights

Current challenges and opportunities in nonclinical safety testing of biologics

Abstract 1604: Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials

Effect of human OX40 ligand fusion protein (MEDI6383) on immune cells of the humoral and cell-mediated immune response in a non-human primate model

Suchergebnisse filtern